Comparative Study to Evaluate Efficacy & Cost Effectiveness of Olmesartan Versus Telmisartan, in Patients of Stage I Hypertension
##plugins.themes.academic_pro.article.main##
Abstract
Background: Hypertension is one of the most common diseases in the world. It is an important and independent risk factor for atherosclerosis, heart failure, renal disease, and peripheral arterial disease. It is directly responsible for 57% of all stroke deaths and 42% of coronary heart disease deaths in India.Objectives: To evaluate and compare efficacy and cost effectiveness in hypertensive patients receiving Olmesartan and Telmisartan in Stage I hypertension.Material and methods: The present study was an open, prospective, randomized, parallel group comparative study conducted in 60 patients of stage I hypertension over a period of 16 weeks. Patients were randomly allocated to two, age and sex, matched groups of 30 patients each. Group I patients were started on Olmesartan at a dose of 20 mg & Group II patients were put on Telmisartan at a dose of 40 mg. The BP lowering efficacy and cost effective analysis of Olmesartan versus Telmisartan was calculated&compared. The data was entered in Microsoft excel and compiled. Statistical analysis was done using various tests.Results: Maximum patients in both the groups were in age group of 51-60 years. In group I there were 13 males and 17 females. In group II there were 14 males and 16 females. Both Olmesartan and Telmisartan are effective in lowering systolic&diastolic BP in supine&sitting positions&mean BP is also lowerer, more in Olmesartan group. By cost effective analysis Telmisartan was found more cost effective. Incremental cost effective ratio was found to be 218.35.Conclusion: Both Olmesartan and Telmisartan belong to the same antihypertensive drug class, effectively reduce systolic and diastolic blood pressure at various visits. Taking into account Total cost Telmisartan was more cost effective than Olmesartan. ICER was found to be 218.35.
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Palta, S., Sehgal, V. K., Gupta, A. K., & Singh, H. (2015). Comparative Study to Evaluate Efficacy & Cost Effectiveness of Olmesartan Versus Telmisartan, in Patients of Stage I Hypertension. International Journal of Medical and Dental Sciences, 568–576. https://doi.org/10.18311/ijmds/2015/19777
References
- Basile JN, Ventura H. A historical look at hypertension: celebrating 100 years with the Southern Medical Association. South Med J 2006;99(12):1412-3.
- Esunge PM. From blood pressure to hypertension: the history of research. Journal of the Royal Society of Medicine 199;84(10):621.
- Michel T, Hoffman B. Treatment of Myocardial Ischemia and Hypertension. In: Brunton LL, Chabner BA, Knollmann BC editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw Hills; 2011.p. 766.
- Venkateswaramurthy M, Dileep M, Perumal P. Management of Hypertension in patients with Diabetes. Asian J Pharm Clin Res 2011;4 Suppl(2):40-41.
- Gupta R. Trends in Hypertension. J Hum Hypertension 2004;8(2):73-8.
- Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365:217–23.
- Pradeepa R, Mohan V. Hypertension & pre-hypertension in developing countries. Indian J Med Res 2008;128:688-690.8 8. Rodrigo M, Premranjan P, Richard W. Diabetes and Hypertension. Natural Clinical Practice 2007;3(10).
- McGhan Williams F. Introduction to Pharmacoeconomics. In: Arnold Renee JG, editors. Pharmacoeconomics from theory to practice. 10th ed. USA: Boca Raton CRC Press; 2010. p.4.
- Chobanian AV, Bakris GL, Black HR, Cushman C, Green Lee A, Izzo JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289(19):560-72.
- Norwood D, Evans B III, Smith B, Honeywell M. Olmesartan Medoximil for Hypertension: A Clinical Review. Drug Forecast 2002;27:611-18.
- Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma inducing activity. Med hypotheses 2005;64.
- Brunner HR. Clinical efficacy and Tolerability of Olmesartan. Clin Ther 2004;26:28-32.
- Nakayama S, Watada H, Mita T, Ikeda F, Shimizu T, Uchino H, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early stage type 2 diabetes with hypertension. Fundam Clin Pharmacol 2007;21(2):181-90.
- Jadhav UM, Anala K, Soniya P. Comparative efficacy of telmisartan 40mg and olmesartan 20mg on 24hours ambulatory blood pressure monitoring in hypertension. The Journal of Clinical Hypertension 2012; 14Suppl (1):20.
- Sasaki T, Noda Y, Yasuoka Y, Irino H, Abe H, Adachi H et al. Comparison of the Effects of telmisartan & olmesartan on home blood pressure, Glucose & lipid profiles in Patients with Hypertension chronic heart failure & metabolic syndrome. Hypertension Research 2008;31:921-29.
- Arao T, Okada Y, Mori Y, Nishida K, Tanaka Y. Antihypertensive & metabolic effects of high dose Olmesartan & Telmisartan in type 2 diabetes patients with hypertension. Endocrine journal 2013; 60(5):563-570.
- Boersma C, Voors AA, Visser ST, De Jong VBLT, Postma MJ. Cost effectiveness of angiotensin receptor blocker monotherapy in Patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data. Am J Cardiovasc Drugs 2010;10(1):49-54.